PATENT CLAIM ANALYSIS

Application Number: 15952017
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-08
Patent Classification: ["548", "112000"]

Abstract:
Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as arthritis.

Claim (Index 10):
The method of  claim 1 , wherein the human being has suffered from arthritis pain for at least 2 months.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 91.0
- Lexical Diversity: 1.25
- Patent Class: 548.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15385415', '15348842', '15439774', '15354908', '15623274']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8292065086592448
- 35 USC 102 Novelty (BERT): 0.5899900648671682
- Combined Prediction Score: 0.8052848642800372
- Mean Citation Score: 673.67468
- Max Citation Score: 681.28015
- Similarity Product: 394.0708447253258

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test